Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.
The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky filed an amended insider report clarifying that a recent transaction was an open-market stock purchase. On this amended Form 4, he is shown buying 10,000 shares of common stock at $10.14 per share. Following this transaction, his direct ownership stands at 61,668.534 shares of DENTSPLY SIRONA common stock. The amendment corrects the original coding of the trade, which had been mistakenly reported as an award rather than a market purchase, while leaving all other details unchanged.
DENTSPLY SIRONA Inc. executive Lindi Rene Barton-Brobst, SVP, GC & Secretary, filed an initial statement of beneficial ownership. She reports 45,185.444 shares of common stock held directly, including 38,743.444 Restricted Stock Units, plus 254.6498 shares held indirectly through a 401(k) plan.
She also holds phantom stock representing 556.7220 equivalent common shares under a Supplemental Executive Retirement Plan, payable in stock upon termination of employment, and multiple stock option grants to buy common shares at exercise prices between $14.7800 and $58.7100 with expirations from 2030 to 2036. The filing lists these positions as holdings rather than reporting new purchases or sales.
DENTSPLY SIRONA Inc. director Clyde Hosein made an open-market purchase of 6,500 shares of common stock at $9.985 per share. Following this transaction, his direct ownership increased to 70,575.456 shares, indicating a higher personal equity stake in the company.
DENTSPLY SIRONA Inc. director Brian P. McKeon reported an open-market purchase of the company’s common stock. On June 12, 2026, a trust associated with him bought 10,000 shares at $10.12 per share, held as indirect ownership. A separate entry shows he directly holds 28,887 common shares following the reported transactions.
DENTSPLY SIRONA Inc. director Brian T. Gladden reported an open-market purchase of 9,985.022 shares of common stock on June 15, 2026. The weighted average purchase price was $10.015 per share, based on multiple trades between $10.015 and $10.0156. Following this transaction, he directly owns 61,848.544 shares of the company’s common stock.
MAZELSKY JONATHAN JAY reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky received a grant of 10,000 shares of Common Stock on June 12, 2026 at a reported value of $10.14 per share. This compensation-related award increased his directly held stake to 61,668.534 shares, rather than reflecting an open-market purchase.
DENTSPLY SIRONA Inc. director Betsy D. Holden purchased additional shares of the company’s Common Stock in the open market. She bought 10,086 shares on June 11, 2026 at a weighted average price of $9.8842 per share. After this transaction, she directly owns 87,528 shares of DENTSPLY SIRONA Common Stock. The filing notes that the purchase price reflects multiple trades executed between $9.865 and $9.90 per share.
DENTSPLY SIRONA Inc. director Michael J. Barber reported an open-market purchase of Common Stock. On June 11, 2026, he bought 15,175 shares at a weighted average price of $9.885 per share, with individual trades ranging from $9.87 to $9.93. Following this transaction, he directly owns 55,943 shares of the company’s stock.
Dentsply Sirona is appointing John C. Fortson as Executive Vice President and Chief Financial Officer, effective July 20, 2026. He brings more than 25 years of leadership experience in finance, operations, and strategy across global manufacturing and industrial businesses, including prior CEO and CFO roles at Ingevity Corporation and senior finance roles at Kymera International and AAR Corp.
Under his offer letter, Fortson will receive a $780,000 annual base salary, a target annual bonus equal to 85% of base salary, and, beginning in 2027, annual equity awards targeted at $2.5 million. He is also entitled to a $500,000 sign-on cash payment and a $700,000 sign-on equity award split between premium stock options and restricted stock units, along with standard executive benefits, severance protections, and a non-competition agreement.
DENTSPLY SIRONA Inc. director Gregory T. Lucier reported a mix of equity awards and family wealth transfers in company stock. He made bona fide gifts of 38,382 shares of Common Stock and 10,900 stock options to a family partnership associated with a trust benefiting him, with his spouse as general partner.
At the same time, he received matching direct awards: 38,382 Restricted Stock Units that vest in full one year from the grant date and 10,900 Non‑Qualified Stock Options with a $9.64 exercise price that vest in one year and expire in 2036. After these transactions, indirect Common Stock holdings reported include 65,000 shares held by a trust and 21,000 shares held in an IRA, while the family partnership is shown with 63,283.284 shares. These moves reflect compensation grants and estate or family planning activity rather than open‑market buying or selling.